Gefitinib v monoterapii u nemocných s pokročilým NSCLC nesoucím aktivující mutaci EGFR zlepšuje významné léčebné výsledky oproti standardní chemoterapii - Aktualita z klinické praxe

Klinicka Onkologie

Volumn 23, Issue 5, 2010, Pages 365-366

  Zemanová, Milada ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78149310321     PISSN: 0862495X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer. results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366: 1527-1537.
2. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol. 2004 Mar 1; 22(5): 777-84.
3. Paez JG, Janne PA, Lee JC et al EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500
4. Mok TS, Wu Y-L, Thongprasert S et al. Gefitinib or carboplatin-pachtaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
5. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121-128.
6. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR. N Engl J Med 2010; 362: 2380-2388.
7. Kim ES, Hirsh V, Mok T et al. Gefitinib versus docetaxel in previously treated nonsmall-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008; 372: 1809-1818.